Table 1.

Effects of GAG preparations on the bioactivity of active TGF-β1a

AdditionsThymidine Incorporation (cpm × 103)
20 × 103 Cells/Well40 × 103 Cells/Well
aTGF-β1, transforming growth factor-β1; GAG, glycosaminoglycan; mH, modified heparin; DS, dermatan sulfate. TGF-β1 bioactivity was assessed using the mink lung cell assay, as described in Materials and Methods. Mink lung cells (20 × 103 or 40 × 103 cells/well) were incubated with growth medium, with or without 1 ng/ml recombinant active TGF-β1, in the presence or absence of 10 μg/ml GAG/mH or GAG/DS. After 24 h, the incorporated [3H]thymidine (used as a marker of DNA synthesis) was measured. Values are the mean ± SEM of triplicate determinations.
bP < 0.005 versus no TGF-β1.
cP > 0.05, NS versus TGF-β1 without GAG.
None29.1 ± 5.291.5 ± 8.7
GAG/mH31.2 ± 2.486.5 ± 8.6
GAG/DS25.6 ± 4.281.7 ± 9.8
TGF-β14.1 ± 3.7b31.5 ± 6.6b
TGF-β1 + GAG/mH2.1 ± 1.9b,c28.7 ± 3.9b,c
TGF-β1 + GAG/DS1.8 ± 1.5b,c27.9 ± 6.4b,c